The effect clinical trial results can have on a pharma company’s stock are tremendous and can work both ways. Disappoint investors and a sharp descent for the shares is likely. Conversely, release encouraging news, and the sky’s the limit. It is safe to say that …
See Original Article
Perhaps most noteworthy is that the device — unlike virtually every other product intended to prevent snoring and sleep apnea — is for use only when the patient is awake. Specifically, the FDA explained, patients use …
See Original Article
Responsibilities include basic, hands-on bookkeeping and accounting, assisting with budgeting and financial planning, preparing financial reports, and
See Original Article
O2Micro reported fourth-quarter sales of $23.2 million, up 30% year over year, which narrowly missed Wall Street’s estimate of $23.3 million. But the company’s fully diluted EPS of $0.14 beat the consensus estimate of $0.10.
See Original Article
Palantir has been working with BP since 2014, with Palantir saying that its data analytics software “has been a key accelerant in BP’s digital transformation.” The new deal commits BP to use Palantir’s tools for an additional five years.
See Original Article